Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab in HBV on Suppressive Antiviral Therapy
NCT04046107Phase 2Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2024
- Primary completion
- Sep 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 4
01
Overview
A Phase 2 trial of cemiplimab in Chronic Hepatitis B (CHB), sponsored by National Institute of Allergy and Infectious Diseases. Planned start Jan 2024; status: withdrawn.
02
Drugs
cemiplimab
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04046107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04046107.